Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

City paying little heed to latest Shire scare story

Shire has agreed to be taken over by Takeda of Japan in a £46bn deal
City paying little heed to latest Shire scare story
Traders didn't seem unduly concerned by the latest threat to the takeover

Shares in Shire PLC (LON:SHP) were up marginally in afternoon trade, suggesting the market is according little credence to the latest scare story dogging the UK drugs giant’s £46bn takeover.

According to newswire reports, former employees accounting for around 1% of bidder Takeda Pharmaceutical Co’s (TYO:4502) shareholder register want to block the deal.

“Last year, the same group attempted to prevent the appointment of outgoing chairman Yasuchika Hasegawa to an advisory position at the company,” Reuters pointed out.

“Although the proposal was defeated at the company's annual general meeting, it gained 30.5 percent of votes.”

Square Mile sanguine 

The Square Mile remained sanguine about the prospect, with Shire stock changing hands for £40.18, up around 19 pence.

Last month, Shire’s board unanimously agreed a £46bn bid tabled by its Japanese drugs rival, having spurned four previous approaches.

The clincher appeared to be the cash component of the transaction, which has been boosted to around £24 a share, making up just under half the £49.01 a share offered by the Japanese company.

Since then, the headline value has receded as Takeda’s stock has fallen.

Shire shareholders will own about half of the combined group after the deal, which will be the biggest takeover in the sector since 2000 if approved by shareholders.

View full SHP profile View Profile

Shire Plc Timeline

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
October 25 2018
The partnership with the US-based network will give Paradigm substantial exposure and access to a large patient pool.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use